Becton, Dickinson and Company (BDX) Position Held by GVO Asset Management Ltd
GVO Asset Management Ltd continued to hold its stake in Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,500 shares of the medical instruments supplier’s stock at the end of the 2nd quarter. Becton, Dickinson and makes up approximately 0.5% of GVO Asset Management Ltd’s portfolio, making the stock its 17th biggest position. GVO Asset Management Ltd’s holdings in Becton, Dickinson and were worth $2,244,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. BlackRock Inc. increased its holdings in Becton, Dickinson and by 2,427.8% during the 1st quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock worth $3,034,470,000 after purchasing an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. increased its holdings in Becton, Dickinson and by 5.3% during the 1st quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock worth $2,917,094,000 after purchasing an additional 796,034 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Becton, Dickinson and during the 1st quarter worth approximately $101,993,000. Waverton Investment Management Ltd bought a new stake in Becton, Dickinson and during the 2nd quarter worth approximately $68,448,000. Finally, Montag & Caldwell LLC increased its holdings in Becton, Dickinson and by 173.1% during the 2nd quarter. Montag & Caldwell LLC now owns 516,821 shares of the medical instruments supplier’s stock worth $100,837,000 after purchasing an additional 327,587 shares in the last quarter. 87.12% of the stock is owned by institutional investors and hedge funds.
In other news, EVP Linda M. Tharby sold 4,695 shares of Becton, Dickinson and stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $200.48, for a total transaction of $941,253.60. Following the transaction, the executive vice president now owns 18,670 shares in the company, valued at approximately $3,742,961.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Thomas E. Polen, Jr. sold 5,971 shares of Becton, Dickinson and stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at approximately $2,538,890.01. The disclosure for this sale can be found here. Insiders have sold a total of 75,904 shares of company stock worth $15,242,688 in the last quarter. Corporate insiders own 1.40% of the company’s stock.
A number of analysts have commented on the company. Wells Fargo & Company assumed coverage on Becton, Dickinson and in a report on Friday. They set an “outperform” rating and a $225.00 price objective for the company. Piper Jaffray Companies reissued a “buy” rating and set a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Monday, August 14th. Cowen and Company reissued a “buy” rating and set a $230.00 price objective on shares of Becton, Dickinson and in a report on Monday, August 14th. Finally, Barclays PLC restated an “equal weight” rating and issued a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Five research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $200.93.
Shares of Becton, Dickinson and Company (NYSE BDX) opened at 193.06 on Friday. The stock has a market cap of $43.93 billion, a P/E ratio of 55.91 and a beta of 1.06. The firm’s 50 day moving average price is $199.01 and its 200 day moving average price is $191.58. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63.
Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. The business had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company’s revenue was down 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.35 EPS. On average, analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a dividend yield of 1.51%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/becton-dickinson-and-company-bdx-position-held-by-gvo-asset-management-ltd/1584139.html.
Becton, Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.